Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates - Seite 3

At the upcoming American Society of Clinical Oncology (ASCO) ASCO20 Virtual Scientific Program, the following Merus abstracts and poster presentations will be reported:

      -    Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients who had progressed on anti-HER2 ADCs. Abstract # 3093
The triplet Zeno combination is active in heavily pretreated patients with HER2+/amplified MBC and is safe and well tolerated. Twenty-eight patients  with a median of 3 prior lines of anti-HER2 therapy in the metastatic setting received a median of 5 Zeno treatment cycles. Of 26 evaluable patients, the disease control rate was 77% with 1 confirmed CR and 4 unconfirmed partial responses. Data on primary endpoint, clinical benefit rate at 24 weeks overall response rate and pharmacokinetics (PK) will be presented.
             
      -    Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients with ER-resistant disease who had progressed on a CDK4/6 inhibitor. Abstract # 1037
The addition of Zeno to the last line of endocrine therapy showed clinical activity and a favorable safety profile. Forty-eight patients with a median of 2 prior lines of endocrine therapy and 1 prior line of chemotherapy, had all previously progressed on a CDK4/6i. Of 42 evaluable patients, the disease control rate was 45% with 2 unconfirmed partial responses. Data on primary endpoint, clinical benefit rate at 24 weeks, overall response rate and (PK) will be presented.

MCLA-117 (CLEC12A x CD3 Biclonics): Acute Myeloid Leukemia (AML)  

MCLA-117 Phase 1 interim data

MCLA-117 is a bispecific (Biclonics) T-cell engager antibody that is designed to engage CD3 on T-cells and to bind to and kill AML blasts via the CLEC12A antigen. It is currently being evaluated in a Phase 1 trial is a single-arm, open-label, global study to assess the safety, tolerability and anti-tumor activity of MCLA-117 currently enrolling patients with relapsed/refractory AML.